On August 11, 2025, NRX Pharmaceuticals announced that the FDA granted Fast Track designation for NRX-100, its ketamine formulation for treating suicidal ideation. Additionally, the FDA identified some deficiencies in the ANDA application, including missing batch records and a 6% difference in an inactive ingredient, which the company plans to address promptly.